Press "Enter" to skip to content

Patent delisted for Daiichi Sankyo drug BENICAR HCT

1
Copyright © DrugPatentWatch. Originally published at Patent delisted for Daiichi Sankyo drug BENICAR HCT

Annual Drug Patent Expirations for BENICAR+HCT
Benicar Hct is a drug marketed by Daiichi Sankyo and is included in one NDA. It is available from three suppliers.

BENICAR HCT drug price trends.

Drug patent litigation for BENICAR HCT.

The generic ingredient in BENICAR HCT is hydrochlorothiazide; olmesartan medoxomil. Three suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Daiichi Sankyo drug BENICAR HCT
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions